Retinoic Acid Profiles in Proliferative Verrucous versus Homogeneous Leukoplakia: A preliminary nested case–control study

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Cirurxía e Especialidades Médico-Cirúrxicas
dc.contributor.affiliationUniversidade de Santiago de Compostela. Instituto de Materiais (iMATUS)
dc.contributor.authorChamorro Petronacci, Cintia Micaela
dc.contributor.authorPérez Jardón, Alba
dc.contributor.authorBravo López, Susana Belén
dc.contributor.authorGándara Vila, Pilar
dc.contributor.authorBlanco Carrión, Andrés
dc.contributor.authorAvila Granizo, Yajaira Vanessa
dc.contributor.authorLorenzo Pouso, Alejandro Ismael
dc.contributor.authorPrieto Barros, Sara Alexandra
dc.contributor.authorPérez-Sayáns García, Mario
dc.date.accessioned2025-12-05T07:24:05Z
dc.date.available2025-12-05T07:24:05Z
dc.date.issued2025-08-02
dc.description.abstractBackground: Oral leukoplakia (OL) and proliferative verrucous leukoplakia (PVL) remain challenging entities due to the absence of reliable prognostic biomarkers. All-trans retinoic acid (atRA), a pivotal modulator of epithelial differentiation and mucosal integrity, has been proposed as a candidate biomarker. This study sought to quantify plasma RA levels in patients with OL and PVL compared to healthy controls, assessing their potential clinical utility. Methods: A cohort of 40 participants was recruited, comprising 10 patients with OL, 10 with PVL, and 20 healthy controls. This nested case–control study was derived from previously characterized institutional databases of oral potentially malignant disorders. Plasma samples were analyzed for atRA concentration using high-precision mass spectrometry. Statistical comparisons were conducted to evaluate differences between groups and associations with clinical outcomes. Results: Patients with homogeneous OL exhibited significantly reduced plasma atRA concentrations (mean 2.17 ± 0.39 pg/mL) relative to both PVL patients (2.64 ± 0.56 pg/mL) and healthy controls (2.66 ± 0.92 pg/mL), with p-values of 0.009 and 0.039, respectively. No statistically significant difference was found between PVL patients and controls. Furthermore, atRA levels demonstrated no correlation with clinicopathological variables or malignant progression within the PVL cohort. Conclusions: These preliminary findings indicate that diminished plasma atRA levels may serve as a prognostic marker for homogeneous oral leukoplakia, whilst its role in PVL appears limited. However, effect estimates were imprecise, and additional studies are warranted.
dc.description.peerreviewedSI
dc.identifier.citationChamorro-Petronacci, C. M., Pérez-Jardón, A., Bravo, S. B., Gándara-Vila, P., Blanco-Carrión, A., Avila-Granizo, Y. V., Lorenzo-Pouso, A. I., Prieto-Barros, S. A., & Pérez-Sayáns, M. (2025). Retinoic Acid Profiles in Proliferative Verrucous Versus Homogeneous Leukoplakia: A Preliminary Nested Case–Control Study. Biomedicines, 13(8), 1881. https://doi.org/10.3390/biomedicines13081881
dc.identifier.doi10.3390/biomedicines13081881
dc.identifier.issn2227-9059
dc.identifier.urihttps://hdl.handle.net/10347/44249
dc.issue.number8
dc.journal.titleBiomedicines
dc.language.isoeng
dc.page.initial1881
dc.publisherMultidisciplinary Digital Publishing Institute MDPI
dc.relation.publisherversionhttps://doi.org/10.3390/biomedicines13081881
dc.rights© 2025 by the authors. Creative Commons Attribution (CC BY) license
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectRetinoic acid
dc.subjectMouth neoplasm
dc.subjectOral leukoplakia
dc.subjectProliferative verrucous leukoplakia
dc.subjectMass spectrometry
dc.subject.classification321313 Ortodoncia-estomatología
dc.titleRetinoic Acid Profiles in Proliferative Verrucous versus Homogeneous Leukoplakia: A preliminary nested case–control study
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication
relation.isAuthorOfPublicationfba09624-8717-4db3-afdd-e018d34469f3
relation.isAuthorOfPublication08ff9542-3871-43fe-8068-7b7378bcd747
relation.isAuthorOfPublication1fc179e1-51df-42a8-8961-420b8d496a9e
relation.isAuthorOfPublication.latestForDiscoveryfba09624-8717-4db3-afdd-e018d34469f3

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2025_biomedicines_Chamorro_Retinoic.pdf
Size:
703.29 KB
Format:
Adobe Portable Document Format